Trial reportJournal of clinical hypertension (Greenwich, Conn.)2018
Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study.
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.Journal of the American Heart Association · 2020Pooled it
- Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study.Journal of clinical hypertension (Greenwich, Conn.) · 2018Trial
- Correlation between the utilization of sodium-glucose cotransporter-2 (SGLT2) inhibitors and the risk of dementia: a nationwide population-based study in Taiwan.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes.International journal of molecular sciences · 2025Review
- Nutriomics and artificial intelligence nutrition obesity cohort (NAINOC): a design paper for a prospective cohort for nutrition and obesity research.Clinical hypertension · 2025Article
- The Effects of SGLT2 Inhibitors on Blood Pressure and Other Cardiometabolic Risk Factors.International journal of molecular sciences · 2024 · on this mapReview
- Clinical studies on pharmacological treatment of hypertension in Japan.Journal of human hypertension · 2024Review
- Associations of SGLT2 genetic polymorphisms with salt sensitivity, blood pressure changes and hypertension incidence in Chinese adults.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs.Metabolites · 2023Review
- Sympathetic modulation by antihypertensive drugs.Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
- Clinical significance of nocturnal home blood pressure monitoring and nocturnal hypertension in Asia.Journal of clinical hypertension (Greenwich, Conn.) · 2021Review
- Office blood pressure threshold of 130/80 mmHg better predicts uncontrolled out-of-office blood pressure in apparent treatment-resistant hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2021Observational
- Randomized, "head-to-head" studies comparing different SGLT2 inhibitors are definitely needed.Journal of clinical hypertension (Greenwich, Conn.) · 2020Article
- Prevalence and prognosis of the 2018 vs 2008 AHA definitions of apparent treatment-resistant hypertension in high-risk hypertension patients.Journal of clinical hypertension (Greenwich, Conn.) · 2020Article
- A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial.Journal of clinical hypertension (Greenwich, Conn.) · 2020Article
- Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study.Journal of clinical hypertension (Greenwich, Conn.) · 2020Article
- Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.Annals of medicine · 2020Review
- Asian management of hypertension: Current status, home blood pressure, and specific concerns in Japan.Journal of clinical hypertension (Greenwich, Conn.) · 2020Review
- The HOPE Asia Network activity for "zero" cardiovascular events in Asia: Overview 2020.Journal of clinical hypertension (Greenwich, Conn.) · 2020Review
- Key Points of the 2019 Japanese Society of Hypertension Guidelines for the Management of Hypertension.Korean circulation journal · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have beneficial effects on several cardiometabolic biomarkers, but this is not sufficient to fully explain the significant reduction in cardiovascular risk and mortality reported with SGLT2 inhibitor treatment in patients with diabetes mellitus. The 8-week, randomized, open-label SHIFT-J study investigated the effects of adding canagliflozin vs intensified antihyperglycemic therapy on nocturnal home blood pressure (BP) in patients with poorly controlled type 2 diabetes and nocturnal BP on existing therapy. Patients were randomized to oral canagliflozin 100 mg/d or control (increased hypoglycemic dosage/addition of another hypoglycemic agent). The efficacy analysis included 78 patients (mean 69 years; 59% male). Nocturnal home systolic BP [HSBP] decreased by 5.23 mm Hg in the canagliflozin group and by 1.04 mm Hg in the control group (P = 0.078 for between-group difference in change from baseline to week 8 [primary endpoint]); corresponding decreases in HSBP from baseline to week 4 were 5.08 and 1.38 mm Hg, respectively (P = 0.054). Reductions in morning HSBP from baseline to week 4 (-6.82 mm Hg vs -1.26 mm Hg, P = 0.038) and evening HSBP from baseline to week 8 (-8.74 mm Hg vs -2.36 mm Hg, P = 0.012) were greater in the canagliflozin group than in the control group. Body mass index (P < 0.001) and N-terminal pro B-type natriuretic peptide level (NT-proBNP; P = 0.023) decreased more in the canagliflozin group than in the control group. Glycemic control improved comparably in both groups. Reduction of HSBP and NT-proBNP level may be potential mechanism by which SGLT2 inhibitors reduce cardiovascular event risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.